



Partner Profile: Jonathan Couchman

Belgrave Hall Belgrave St.
Leeds LS2 8DD UK

Tel: +44(0) 113 233 0143
Mob: +44(0) 777 030 2653
Fax: +44(0) 113 233 0101

Email: jcouchman@hgf.com
Web: www.hgf.com

MA (Cantab)

Chartered Patent Attorney, European Patent Attorney,
Registered Trade Mark Attorney

Partner

Jonathan's practice is principally in pharmaceuticals, including strategic advice relating to biologicals, as well as more widely in organic chemistry and the interface between chemistry and biology. His work includes providing quasi in-house advice on life cycle management of pharmaceuticals. Clients in other technologies also value Jonathan's aggressive approach to protecting their rights and his successful record in protecting inventions at the margins of patentability.

The cornerstone of Jonathan's practice is the pharmaceutical industry, where Jonathan's clients include a top ten major and an Anglo-German pharmaceutical development company whose IP portfolio is managed by HGF. Jonathan has developed a team of medicinal chemistry and biotechnology professionals at HGF to handle the growing workload from the pharma sector, which includes drafting and prosecution of patent applications for new chemical and biological entities, uses and

formulations as well as due diligence work and consultancy. Jonathan's own consultancy work has included advising in relation to patent defence of one of the global top 20 prescription drugs.

Outside the pharmaceutical field, Jonathan's practice includes research tools, with a particular focus on fluorescent labeling technology, and nanotechnology where Jonathan and his group at HGF are proud to represent a team led by a Nobel laureate.

Jonathan's early professional experience was in private practice firms in London, before moving into partnership outside the city in 1989 to fulfill a desire for a more entrepreneurial life. Since then, Jonathan has worked outside London and developed a strong client base in his chosen practice areas. He joined Harrison Goddard Foote in 1997 as the firm's third partner (and third fee earner) and has since then participated in the more than tenfold growth of its fee earners.